The UBE2J2/UBE2K-MARCH5 ubiquitination machinery regulates apoptosis in response to venetoclax in acute myeloid leukemia

Leukemia. 2024 Mar;38(3):652-656. doi: 10.1038/s41375-024-02178-x. Epub 2024 Feb 16.

Authors

Shan Lin^#^{1

2}, Constanze Schneider^#^{1

2}, Angela H Su^{1

2}, Gabriela Alexe^{1

2}, David E Root², Kimberly Stegmaier^{3

4

5}

Affiliations

¹ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Broad Institute of MIT and Harvard, Cambridge, MA, USA.
³ Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
⁴ Broad Institute of MIT and Harvard, Cambridge, MA, USA. [email protected].
⁵ Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. [email protected].

^# Contributed equally.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Apoptosis
Bridged Bicyclo Compounds, Heterocyclic / pharmacology
Humans
Leukemia, Myeloid, Acute* / drug therapy
Proto-Oncogene Proteins c-bcl-2 / metabolism
Sulfonamides*
Ubiquitin-Conjugating Enzymes
Ubiquitination

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Proto-Oncogene Proteins c-bcl-2
UBE2K protein, human
Ubiquitin-Conjugating Enzymes
UBE2J2 protein, human
Sulfonamides

Grants and funding